Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in bipolar disorder. The BXCL501-302 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in agitation associated with bipolar disorder.
Epistemonikos ID: bb6e978f09078f9ede1853c81a6eae480c713526
First added on: May 07, 2024